Jaguar Health, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
JAGX$0.44+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, | ||||
| (in thousands) · 2025 · 2024 | ||||
| Cash flows from operating activities | ||||
| Net comprehensive loss | $ | (31,222) | $ | (29,057) |
| Adjustments to reconcile net comprehensive loss to net cash used in operating activities: | ||||
| Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option | 4,721 | 6,920 | ||
| Loss (gain) on extinguishment of debt | 1,822 | (1,245) | ||
| Depreciation and amortization expenses | 1,436 | 1,422 | ||
| Stock-based compensation, vested and released restricted stock units, and exercised stock options | 715 | 1,269 | ||
| Amortization of operating lease - right-of-use asset | 223 | 343 | ||
| Share in joint venture's loss | 120 | 78 | ||
| Amortization of debt issuance costs, debt discount, and non-cash interest expense | — | 274 | ||
| Shares issued in exchange for services | — | 9 | ||
| Changes in assets and liabilities | ||||
| Accounts receivable | 90 | 718 | ||
| Other receivable | 63 | 160 | ||
| Inventory | (283) | (485) | ||
| Prepaid expenses and other current assets | (859) | (1,703) | ||
| Other assets | 108 | (331) | ||
| Accounts payable | 3,097 | (423) | ||
| Accrued liabilities | 2,109 | 65 | ||
| Deferred revenue | (128) | 765 | ||
| Operating lease liability | (210) | (337) | ||
| Total cash used in operating activities | (18,198) | (21,558) | ||
| Cash flows from investing activity | ||||
| Purchase of furniture and fixtures | (54) | — | ||
| Purchase of equipment | — | (16) | ||
| Total cash used in investing activity | (54) | (16) | ||
| Cash flows from financing activities | ||||
| Proceeds from issuance of shares in At the Market offering, net of issuance and offering costs of $161 and $127 in 2025 and 2024, respectively | 6,331 | 27,759 | ||
| Proceeds from Convertible Notes | 3,445 | — | ||
| Proceeds from issuance of preferred shares in PIPE financing, net of issuance cost | 2,377 | — | ||
| Proceeds from issuance of common shares to HCW investors | 1,309 | — | ||
| Proceeds from issuance of common shares to Brown Stone Capital Limited | 1,000 | — | ||
| Repayment of insurance financing | (482) | (437) | ||
| Payment of Tempesta Note | (50) | (100) | ||
| Payment of Convertible Notes | (50) | — | ||
| Proceeds from issuance of common shares in exchange for License Agreement | — | 1,150 | ||
| Total cash provided by financing activities | 13,880 | 28,372 | ||
| Effects of foreign exchange rate changes on assets and liabilities | (103) | 2 | ||
| Net increase (decrease) in cash | (4,475) | 6,800 | ||
| Cash at beginning of the period | 8,002 | 6,469 | ||
| Cash at end of the period | $ | 3,527 | $ | 13,269 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
| Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, | ||||
| 2025 · 2024 | ||||
| Supplemental schedule of cash flow information | ||||
| Cash paid for interest | $ | 15 | $ | 14 |
| Supplemental schedule of non-cash financing and investing activities | ||||
| Preferred stock issued to Iliad in exchange of notes payable and accrued interest | $ | 4,800 | $ | — |
| Preferred stock issued in exchange of another class of preferred stock | $ | 2,485 | $ | — |
| Preferred stock issued to Streeterville in exchange for notes payable and accrued interest | $ | 2,250 | $ | 4,485 |
| Common shares issued to Irving in exchange of notes payable and accrued interest | $ | 1,210 | $ | — |
| Common stock issued to Iliad in exchange for notes payable and accrued interest | $ | 1,100 | $ | 4,906 |
| Common stock issued to Streeterville in exchange for notes payable and accrued interest | $ | 983 | $ | 166 |
| Common stock issued to notes holder in exchange of convertible notes payable and accrued interest | $ | 865 | $ | — |
| First Insurance Financing | $ | 681 | $ | 519 |
| Recognition of operating lease - right-of-use asset and operating lease liability | $ | 341 | $ | 219 |
| Common stock issued to Streeterville in exchange for Series J Preferred Stock | $ | — | $ | 1,999 |
| Umbrella Insurance Financing | $ | — | $ | 52 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.